Comparative Pharmacology
Head-to-head clinical analysis: SODIUM PHOSPHATE P 32 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM PHOSPHATE P 32 versus XENOVIEW.
SODIUM PHOSPHATE P 32 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical